AbstractBackgroundDextromethorphan (DXM) is an over‐the‐counter drug that is commonly abused by teenagers. Its main pharmacological property is a low‐affinityN‐methyl‐d‐aspartate (NMDA) receptor antagonist.Case PresentationWe report acute psychotic dissociation induced by DXM and alcohol in a pa...
AUVELITY is a novel, oral, NMDA receptor antagonist with multimodal activity approved for the treatment of MDD in adults. AUVELITY is a proprietary extended-release oral tablet containing dextromethorphan HBr (45 mg) and bupropion HCl (105 mg). The dextromethorphan component of AUVELITY is an an...
& NEILL, J. C. 2017. NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology.Cadinu D,Grayson B,Podda G,et al. NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel ...
After 24 h the last threshold determination rats received a bilateral VM microinjection of the NMDA antagonist PPPA (0.825 nmol per 0.5 ml per side) and reward thresholds were measured again immediately after the injection for 120 min. siRNA and Drug Downregulation of selective NMDAR subunits was...
However, determination of NMDA receptor antagonist activity for norketamine indicated that this compound is 7–10 times less potent than ketamine (Far- ber and Olney, unpublished data), so that even terminal norketamine levels were unlikely to contribute signifi- cantly to any NRH-induced clinical ...
One such treatment comprises administering a 5HT-2A receptor agonist as a safener drug which accompanies an NMDA antagonist drug that is being used for a therapeutic purpose.Another method disclosed herein involves the use of a 5HT-2A ... JW Olney,NB Farber - US 被引量: 95发表: 1999年 Tr...
antagonist in combination with either of the following agents; sodium channel antagonist, nitric oxide synthase inhibitor, glycine site antagonist, potassium channel opener, AMPA/kainate receptor antagonist, calcium channel antagonist, GABA-A receptor modulator, anti-inflammatory agent or a thrombolytic ...
专利名称：Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis 发明人：John W. Olney,Ronald E. Harbut,Graeme E.Correll,Patrick D. Kelly 申请号：US10786212 申请日：20040226 公开号：US20050222270A1 公开日：20051006 专利内容由知识产权出版社提供 ...
Down syndrome (DS) is the most common genetic cause of intellectual disability. The N-methyl-D-aspartate (NMDA) receptor uncompetitive antagonist, memantine hydrochloride (memantine), has been shown to improve learning/memory and rescue one form of hippo
Recent clinical studies have shown that a single subanesthetic dosage of the non-competitive N-methyl-D-aspartate receptor (NMDARs) antagonist, ketamine, produces a rapid and lasting antidepressant effect in patients who were resistant to the current treatment (Maeng et al, 2008). These findings ...